Table 5.
Mean values (SD) at the start, completion, and follow-up of psychological treatment on the outcome instruments for all patients and categorized by gender, distinguishing between patients with and without hazardous alcohol use. The patients who rated themselves as non-hazardous alcohol users or hazardous users at the start belong to the same groupings at completion and follow-up, regardless of their alcohol consumption at those latter points in Table 5.
| Start | Completion | Follow-up | P-value1 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | No hazardous use N 226 |
Hazardous use N 98 |
P-value1 | N | No hazardous use at start** N 145 |
Hazardous use at start ** N 64 |
P-value1 | N | No hazardous use at start** N 104 |
Hazardous use at start** N 36 |
|||
| All | |||||||||||||
| BAI | 324 | 23.4 (11.8) | 27.2 (12.3) | 0.014* | 209 | 18.2 (12.1) | 17.2 (11.5) | 0.61 | 140 | 17.8 (13.1) | 20.2 (13.6) | 0.36 | |
| MADRS-S | 324 | 23.2 (9.1) | 25.4 (8.3) | 0.069 | 206 | 16.8 (10.6) | 16.1 (9.2) | 0.84 | 140 | 16.2 (10.6) | 17.5 (10.3) | 0.42 | |
| SCL-90 | 324 | 131.3 (57.5) | 160.9 (49.1) | <0.001* | 207 | 102.8 (67.4) | 101.2 (62.8) | 0.96 | 140 | 103.2 (67.3) | 111.6 (67.9) | 0.41 | |
| Q-LES-Q | 324 | 37.6 (9.4) | 36.6 (8.4) | 0.42 | 209 | 42.4 (11.2) | 44.2 (10.8) | 0.36 | 140 | 42.3 (11.3) | 42.0 (12.3) | 0.62 | |
| N 164 | N 62 | N 112 | N 43 | N 76 | N 29 | ||||||||
| Female | |||||||||||||
| BAI | 226 | 25.1 (11.5) | 29.9 (12.2) | 0.015* | 155 | 20.1 (12.1) | 18.9 (11.7) | 0.66 | 105 | 19.9 (13.4) | 21.5 (14.5) | 0.71 | |
| MADRS-S | 226 | 23.9 (9.2) | 25.3 (7.9) | 0.45 | 153 | 17.7 (10.6) | 16.4 (9.5) | 0.61 | 105 | 16.9 (11.0) | 18.7 (10.4) | 0.32 | |
| SCL-90 | 226 | 138.7 (54.3) | 168.2 (47.3) | < 0.001* | 155 | 112.9 (66.6) | 107.7 (63.5) | 0.67 | 105 | 111.5 (68.8) | 118.9 (72.1) | 0.50 | |
| Q-LES-Q | 226 | 36.8 (9.3) | 35.4 (8.9) | 0.34 | 155 | 41.2 (11.1) | 44.1 (11.2) | 0.18 | 105 | 41.2 (11.5) | 41.8 (12.6) | 0.83 | |
| N 62 | N 36 | N 33 | N 21 | N 28 | N 7 | ||||||||
| Male | |||||||||||||
| BAI | 98 | 18.8 (11.4) | 22.7 (11.2) | 0.11 | 54 | 11.9 (9.8) | 13.7 (10.5) | 0.44 | 35 | 12.2 (10.5) | 14.9 (7.0) | 0.31 | |
| MADRS-S | 98 | 21.5 (8.9) | 25.6 (9.2) | 0.032* | 53 | 13.6 (10.3) | 15.5 (8.7) | 0.31 | 35 | 14.4 (9.5) | 12.4 (9.1) | 0.63 | |
| SCL-90 | 97 | 111.5 (61.6) | 148.3 (50.2) | 0.002* | 52 | 68.8 (59.2) | 86.7 (60.5) | 0.21 | 35 | 80.8 (58.6) | 81.5 (36.9) | 0.70 | |
| Q-LES-Q | 98 | 39.7 (9.5) | 38.5 (7.3) | 0.48 | 54 | 46.6 (10.9) | 44.4 (10.3) | 0.48 | 35 | 45.3 (10.3) | 42.7 (12.0) | 0.82 | |
1 Wilcoxon test. * Significant outcomes. ** Belong to the same cluster of patients as at the start of psychological treatment regardless their rated audit score at completion and at follow-up.